Cresset Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Cresset Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$157K	–	799
2022 Q3	$157K	Sell	15,000 -1,685	-10%	-$18.8K	﹤0.01%	814
2022 Q2	$173K	Sell	16,685 -347	-2%	-$2.86K	﹤0.01%	852
2022 Q1	$161K	Sell	17,032 -36,086	-68%	-$338K	﹤0.01%	924
2021 Q4	$613K	Buy	53,118 +4,621	+10%	+$51.5K	0.01%	627
2021 Q3	$463K	Buy	48,497 +11,639	+32%	+$119K	0.01%	654
2021 Q2	$355K	Buy	+36,858	New	+$360K	0.01%	694
2019 Q2	–	Sell	-346	Closed	-$5K	–	896
2019 Q1	$5K	Hold	346	–	–	﹤0.01%	1362
2018 Q4	$3K	Buy	+346	New	+$3.8K	﹤0.01%	1182

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cresset Asset Management's FOLD Position: Q4 2022 in Review

Cresset Asset Management sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 15,000 shares — an estimated $157K sold.

Cresset Asset Management first reported a position in FOLD in Q4 2018 and held it in 8 quarters. The position peaked at $613K in Q4 2021. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

Cresset Asset Management reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
Cresset Asset Management sold 15,000 Amicus Therapeutics shares in Q4 2022, an estimated $157K.
Cresset Asset Management first reported a position in Amicus Therapeutics in Q4 2018 and held it in 8 quarters.
Cresset Asset Management's Amicus Therapeutics position peaked at $613K in Q4 2021.
230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Cresset Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.